This cross-sectional study assessed 15 patients with ST-elevation myocardial infarction (STEMI) presenting to the Punjab Institute of Cardiology in Lahore. The primary objective was to determine the prognostic significance of admission CK-MB and CPK levels in predicting adverse outcomes. No comparator group was reported, and the study design does not establish causality.
Among the 15 patients, CK-MB elevation was observed in 80% (12 of 15), and CPK elevation was also present in 80% (12 of 15). When both markers were elevated concurrently, this occurred in 73.3% (11 of 15) of the cohort. Troponin-I elevation was noted in 86.7% (13 of 15) of the patients. The study also examined associations with hematological parameters, finding that anemia affected 60% of patients, WBC elevation was present in 53.3%, and RBC reduction occurred in 40%.
A significant correlation between CK-MB and CPK levels was identified (r = 0.615, p = 0.0126). However, correlations between cardiac biomarkers and hematological parameters were weak, with p-values greater than 0.05. Electrolyte abnormalities involving sodium, potassium, or bicarbonate were not observed (0%). High-risk patients were identified in 53.3% of the cohort. The study did not report adverse events, discontinuations, or specific follow-up duration.
The authors note that CK-MB and CPK retain prognostic value in STEMI patients, particularly in resource-limited settings where troponin access may be constrained. Given the small sample size of 15 patients and the cross-sectional design, these findings should be interpreted with caution. Further research is needed to validate these observations in larger, randomized populations.
View Original Abstract ↓
Abstract Background: ST-elevation myocardial infarction (STEMI) is reported to be a leading cause of mortality worldwide. While cardiac troponins are the gold standard for myocardial injury detection but creatine kinase-MB (CK-MB) and total creatine phosphokinase (CPK) retain prognostic use in resource-limited settings. Objective: To evaluate the prognostic significance of admission CK-MB and CPK levels in STEMI patients and to assess their association with hematological parameters for integrated risk stratification. Methods: This cross-sectional study enrolled 15 consecutive STEMI patients from the Punjab Institute of Cardiology, Lahore, during January 2024. Comprehensive laboratory analysis including cardiac biomarkers (CK-MB, CPK, troponin-I, LDH), complete blood count, renal function, serum electrolytes, and metabolic parameters, was performed on admission. Pearson correlation and comparative statistical analyses were also conducted to assess the relationships between cardiac biomarkers and hematological indices. Results: The cohort includes 15 patients (mean age 50.1 +/- 12.2 years; 73.3% male). Cardiac biomarker elevation was prevalent: CK-MB was elevated in 12/15 (80%), CPK was elevated in 12/15 (80%), with concordant elevation in 11/15 (73.3%), which indicates extensive myocardial necrosis. Troponin-I showed the highest elevation rate at 13/15 (86.7%). Hematological abnormalities included anemia (60%), WBC elevation (53.3%), and RBC reduction (40%). Random glucose averaged 150.80 +/- 63.55 mg/dL, with 66.7% highlighted the hyperglycemia. Remarkably, electrolyte balance was preserved in all of the patients (0% sodium, potassium, and bicarbonate abnormalities), indicating maintained homeostasis. Pearson correlation analysis revealed a significant correlation between CK-MB and CPK (r = 0.615, p = 0.0126), while correlations between cardiac biomarkers and hematological parameters were weak (p > 0.05). Risk stratification identified 53.3% of patients as high-risk who required intensive management. Conclusions: CK-MB and CPK demonstrate significant concordance and retain prognostic value in STEMI patients, particularly in resource-limited settings where troponin access may be constrained. While troponin-I remains the most sensitive biomarker, combined assessment of conventional cardiac enzymes supports reliable evaluation of myocardial injury. Hematological parameters reflect systemic response but show limited correlation with cardiac biomarkers.